logo
Nvidia to Pay the U.S. Government 15% of China AI Chip Sales. How Will Its Revenue and Profits Be Impacted?

Nvidia to Pay the U.S. Government 15% of China AI Chip Sales. How Will Its Revenue and Profits Be Impacted?

Yahoo2 days ago
Key Points
Nvidia and AMD have reportedly agreed to give the U.S. government 15% of their revenue from sales of their respective artificial intelligence (AI) data center chips designed for the China market in exchange for obtaining export licenses.
This will be a very minor speed bump for Nvidia, whose revenue growth and profitability are phenomenal.
10 stocks we like better than Nvidia ›
Nvidia (NASDAQ: NVDA) and fellow graphics processing unit (GPU) maker Advanced Micro Devices, or AMD, have agreed to give the U.S. government 15% of their revenue from sales of their respective artificial intelligence (AI) data center chips designed for the China market in exchange for obtaining export licenses for these chips, according to the Financial Times, which first reported the story on Sunday night.
The 15% AI chip revenue deal
The U.S. Commerce Department began issuing export licenses for Nvidia's H20 chip and AMD's MI308 chip on Friday, the Financial Times (FT) reported on Friday.
Nvidia provided a statement to the FT after it broke the government deal story on Sunday night that included the following: "We follow rules the U.S. government sets for our participation in worldwide markets."
Background on Nvidia's H20 chip
Nvidia had designed the H20 AI-enabling GPU specifically for the Chinese market after earlier U.S. export controls, enacted under the administration of President Joe Biden, meant it couldn't sell its more advanced data center AI chips to China.
In mid-April, the Trump administration expanded the restrictions to include the H20. Nvidia immediately halted its sales and took a charge of $4.5 billion on its Q1 results for H20 inventory and purchase commitments.
Then in mid-July, Nvidia emailed investors who subscribe to the company's news and said it was "filing applications to sell the Nvidia H20 GPU again. The U.S. government has assured Nvidia that licenses will be granted, and Nvidia hopes to start deliveries soon."
At the time, there was no mention of giving the government a 15% cut of H20 revenue as a condition for obtaining export licenses.
How will Nvidia's revenue be affected by this deal?
We can get an estimate as to how this deal will affect Nvidia's financial results by looking at the company's fiscal first quarter, which ended on April 27.
In that quarter, Nvidia sold $4.6 billion in H20 chips to China prior to the start of the export controls in mid-April. It said it was unable to ship $2.5 billion in H20 chips that it had already produced due to the export controls. So, had the restrictions not existed, Nvidia would have sold $7.1 billion in H20 chips to China customers in Q1. This amounts to 15.2% of $46.6 billion, which is what its total revenue would have been, absent the export controls.
Over 15% of its total revenue is significant, so you can see the importance of Nvidia's China data center business.
For its fiscal Q2 (which ended July 27), investors should expect Nvidia to report no sales of its H20 chip, because the export restrictions were in place the entire quarter. However, H20 sales should fully rebound in fiscal Q3 (late July to late October).
When Nvidia provided Q2 guidance, it estimated that it would lose about $8 billion in H20 chip sales due to the export controls. So, keeping with roughly the same sequential quarter growth, let's assume Q3 H20 sales will be about $9 billion. In this case, Nvidia would pay the U.S. government $1.35 billion, which is 15% of $9 billion.
While $1.35 billion seems like a huge number, it's only a small percentage of Nvidia's overall quarterly revenue. In Q1, Nvidia's total revenue was $44.1 billion -- and it would have been $46.6 billion, had it not "lost" sales of $2.5 billion due to the export restrictions. That $1.35 billion is only 2.9% of $46.6 billion. But the actual Q3 percentage will be smaller because Nvidia's revenue will be higher in Q3 than Q1.
A revenue loss of somewhere between 2% to 3% of total sales is a very minor speed bump. Moreover, it's a much better situation than having no H20 sales.
How will Nvidia's profitability be affected by this deal?
Giving the government a 15% cut of H20 sales revenue should also negatively affect Nvidia's bottom line. But it should be an extremely minor dent, because Nvidia's data center platform is amazingly profitable. On that note, Nvidia overall is amazingly profitable.
Nvidia doesn't break out its profitability by platform, so we'll have to use its overall numbers. In Q1, Nvidia's adjusted gross margin (gross profit divided by revenue) absent the $4.5 billion H20-related charge was 71.3%. The company provided its adjusted earnings per share (EPS) absent the charge, so I could calculate adjusted net income absent the charge and then from that calculate adjusted net profit margin (net income divided by revenue) absent the charge -- which would have been 56.1%.
In other words, Nvidia converts more than half of its revenue into adjusted profits in a typical quarter, which is just phenomenal. It can easily absorb slightly less profitability on its H20 chips, which, again, account for roughly 15% of its total revenue in a typical quarter.
In short, Nvidia stock's strong upward trajectory should not be hurt by the company having to give the government a slice of its H20 sales.
Should you invest $1,000 in Nvidia right now?
Before you buy stock in Nvidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!*
Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 11, 2025
Beth McKenna has positions in Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices and Nvidia. The Motley Fool has a disclosure policy.
Nvidia to Pay the U.S. Government 15% of China AI Chip Sales. How Will Its Revenue and Profits Be Impacted? was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Social Security 2026 cost-of-living adjustment predicted to increase 2.7%
Social Security 2026 cost-of-living adjustment predicted to increase 2.7%

Yahoo

time5 minutes ago

  • Yahoo

Social Security 2026 cost-of-living adjustment predicted to increase 2.7%

Social Security beneficiaries could see a 2.7% cost-of-living adjustment (COLA) next year, which is slightly more than the 2.5% boost U.S. retirees received this year. The new estimate comes from the Senior Citizens League, an advocacy group, which posted its prediction on its website on Tuesday after the Bureau of Labor Statistics released its latest inflation figures. AARP also released 2026 COLA estimates from experts, such as Mike Lynch, managing director of applied insights at Hartford Funds, who predicted a more modest adjustment in the "low to mid" 2% range, up to 2.7%. The Social Security Administration makes a cost-of-living adjustment each year to ensure benefits payments for U.S. seniors keep pace with inflation. The yearly adjustment, which the agency is scheduled to announce in October, would go into effect in January 2026. The SSA did not immediately respond to CBS MoneyWatch's request for comment. Each fall, the agency uses inflation data from July, August and September to determine the COLA for the next year. The consumer price index (CPI), a basket of goods and services typically bought by consumers that tracks the change in prices on everyday items over time, showed that the inflation rate in July held steady at 2.7% on an annual basis, the same as it was in June. So far, the inflation rate has remained below 3% since the start of 2025. However, experts predict it could inch up later in the year as tariffs put more pressure on consumer prices. Alan Detmeister, an economist at UBS, told CBS MoneyWatch that he estimates headline CPI will rise to 3.7% and core CPI will rise to 3.8% by the second quarter of 2026. Teresa Ghilarducci, a labor economist at New York City's New School, believes inflation will likely rise and is concerned that a moderate cost-of-living adjustment "probably won't be enough to cover the inflation rates that we're headed into," AARP reported. According the the AARP, the 2.5% COLA adjustment introduced this year boosted the average Social Security retiree's payment by about $49 a month. The average monthly Social Security check for all beneficiaries was $1,861 in June 2025 and $2,005 for retired workers, according to the Senior Citizens League. In addition to the COLA, some senior citizens will also benefit from a provision included in President Trump's "big, beautiful bill" which provides a temporary tax deduction of up to $6,000 for Americans aged 65 and older. President Trump says meeting with Russia's Putin is not to broker peace deal in Ukraine Could Tropical Storm Erin become the first Atlantic hurricane of 2025? Trump claims "land swapping" between Russia, Ukraine will happen Sign in to access your portfolio

Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ...
Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ...

Yahoo

time5 minutes ago

  • Yahoo

Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ...

Cash Position: $101.2 million as of June 30, 2025. Debt: No debt reported. Cash Utilization: $12.5 million used in operating activities during the quarter. Runway: More than 3 years at the current adjusted cash utilization rate. Research and Development Expenses: $10 million for the quarter, down from $11.8 million in the same quarter last year. General and Administrative Expenses: $4.5 million for the quarter, up from $2.8 million in the same quarter last year. Net Loss: $13.2 million for the quarter, or $0.16 per share. Warning! GuruFocus has detected 1 Warning Sign with AVXL. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Anavex Life Sciences Corp (NASDAQ:AVXL) presented promising open-label extension data for blarcamesine at the Alzheimer's Association International Conference, showing continued clinically meaningful benefits in early-stage Alzheimer's patients. The company has a strong cash position of $101.2 million with no debt, providing a financial runway of over three years at the current cash utilization rate. Blarcamesine demonstrated a favorable treatment duration to time saved ratio when benchmarked against other treatments like Leqembi and Kisunla. Anavex Life Sciences Corp (NASDAQ:AVXL) is exploring the potential of blarcamesine for broader therapeutic applications, including mild to moderate Alzheimer's disease and other rare diseases. The company is actively engaging with policymakers and exploring strategic partnerships to enhance commercialization efforts for blarcamesine in Europe and potentially other markets. Negative Points Research and development expenses remain high at $10 million for the quarter, with significant spending on manufacturing preparations and trial readiness. The company reported a net loss of $13.2 million for the quarter, equating to a loss of $0.16 per share. There is uncertainty regarding the timeline and outcome of the European Medicines Agency (EMA) review for blarcamesine, with feedback expected in the first quarter of next year. The Parkinson's disease study has been delayed due to challenges in study design and the need to increase the chance of success. Anavex Life Sciences Corp (NASDAQ:AVXL) faces competition from injectable treatments, and there is a need to emphasize the benefits of oral administration to achieve broader market penetration. Q & A Highlights Q: Could you explain the difference in the trajectory of patients in the 4-year open-label extension data for blarcamesine, particularly regarding the ADAS-Cog13 and ADCS-ADL readouts? A: Patients were initially randomized to receive either placebo or blarcamesine. Those who started on blarcamesine from day one showed better outcomes than those who began after the placebo phase. The ADAS-Cog13 is more sensitive to immediate changes, while ADCS-ADL is smoother in trajectory. The key takeaway is to start treatment early and maintain it without interruption for optimal benefits. (Christopher Missling, CEO) Q: Are there plans for Alzheimer's prevention trials with blarcamesine? A: Yes, there are plans for a preventative trial based on preclinical work showing potential in preventing dementia onset in animals. However, executing such a long-term study requires more resources, so the focus is first on bringing the drug to market. (Christopher Missling, CEO) Q: What are the strategic objectives of Anavex's engagement with policymakers and government relations? A: The goal is to raise awareness and emphasize the need for funding and attention to Alzheimer's disease. This involves educating policymakers about the unmet needs of patients with dementia and Alzheimer's, which is a common practice among companies. (Christopher Missling, CEO) Q: What is the status of Anavex's pipeline, particularly regarding Parkinson's and Rett syndrome trials? A: Preparations are underway for manufacturing and trials in Parkinson's disease, Fragile X, and another rare disease. The Parkinson's trial design is being refined to increase the chance of success, while the Rett program is awaiting more clarity on Alzheimer's submissions before proceeding. (Christopher Missling, CEO) Q: How does Anavex plan to commercialize blarcamesine if approved by the EMA? A: All options are open, including partnering with companies for marketing in Europe or going solo if it results in higher shareholder value. The decision will be based on what best serves shareholders. (Christopher Missling, CEO) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.

S&P 500, Nasdaq hover near record highs on September rate cut hopes
S&P 500, Nasdaq hover near record highs on September rate cut hopes

Yahoo

time5 minutes ago

  • Yahoo

S&P 500, Nasdaq hover near record highs on September rate cut hopes

By Johann M Cherian and Sanchayaita Roy (Reuters) - The benchmark S&P 500 and the Nasdaq hovered near record highs on Wednesday as investors were increasingly confident that the Federal Reserve could restart its monetary policy easing cycle next month. Signs that U.S. tariffs on imports have not fully filtered into headline consumer prices came as a relief for investors this week as they scour for insights on the impact trade uncertainty has had on the economy. Despite data showing underlying price pressures were on the rise, markets also factored in recent weakness in the job market and a shake-up at the Federal Reserve as they leaned in favor of a potential dovish move by the central bank in September. Traders are now fully pricing in a 25 basis points interest rate cut, according to the CME's FedWatch Tool, up from 89.2% last week. The central bank last lowered borrowing costs in December. Treasury Secretary Scott Bessent also said he thought an aggressive half-point cut was possible given recent weak employment numbers. Stagflation "was the first word that came to my mind when I saw this CPI report yesterday," said Mark Hackett, chief market strategist at Nationwide, referring to Tuesday's data coming on the heels of a number of other reports pointing to a cooling economy. "The slowdown that we're seeing is probably fairly temporary, at least at this point. So inflation is something that we're absolutely worried about because we saw that uptick." At 12:18 p.m. ET, the Dow Jones Industrial Average rose 363.26 points, or 0.82%, to 44,821.52, the S&P 500 gained 9.34 points, or 0.15%, to 6,455.15 and the Nasdaq Composite advanced 15.77 points, or 0.07%, to 21,697.97. The blue-chip Dow was within 1% away from an all-time high and the Russell 2000 index, which tracks rate-sensitive small-cap companies, added 0.1.3% to hit a six-month high. Investors were also taking notice of other sectors following the recent tech-led rally in U.S. stocks that have pushed valuations of the S&P 500 above long-term averages. Healthcare stocks, which have been beaten down for much of the year, led gains among the 11 S&P 500 sectors with a 1.4% rise, while the tech-heavy Nasdaq 100 index was marginally lower. Later in the day, investors will scrutinize remarks of a number of policymakers, especially Chicago Fed President Austan Goolsbee. CoreWeave, which is backed by Nvidia, slumped 17.6% after the AI data center operator reported a bigger-than-expected quarterly net loss. Eyes are also on developments surrounding the China revenue-sharing deal the U.S. government signed with top chipmakers, which the White House said could be expanded to others in the sector. Paramount Skydance jumped 30%. The company won exclusive broadcasting rights to the Ultimate Fighting Championship for seven years earlier this week. In geopolitics, traders also were keen on a meeting between Trump and Russia's Vladimir Putin on the Ukraine conflict scheduled on Friday. Advancing issues outnumbered decliners by a 2.96-to-1 ratio on the NYSE and by a 2.28-to-1 ratio on the Nasdaq. The S&P 500 posted 37 new 52-week highs and two new lows, while the Nasdaq Composite recorded 131 new highs and 49 new lows. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store